At the advanced stages (American Joint Committee on Cancer), BCAT1 demonstrated diverse expression levels in various cancers—increased levels in kidney renal papillary cell carcinoma, STAD, and testicular germ cell tumors; reduced levels in CHOL, lung adenocarcinoma, pancreatic adenocarcinoma (PAAD), SKCM, and THCA (Figure 5C), suggesting that BCAT1 may play different roles in these cancers. This evidence concerns the gene BCAT1 and lung adenocarcinoma.